Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim corresponds directly to FDA labeling: the label states severe acute hepatitis B exacerbations may occur with discontinuation of BIKTARVY and recommends close clinical and laboratory monitoring for at least several months after stopping.
Category Scores
Accurate Statements
post-treatment acute exacerbation of hepatitis B after discontinuation
FDA label (5.1): “Severe acute exacerbations of hepatitis B ... may occur with discontinuation of BIKTARVY.” Also (5.1) monitoring after stopping.
Patients with HIV-1 and HBV who discontinue BIKTARVY should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.
FDA label (5.1): “closely monitored ... for at least several months after stopping treatment.”
Severe acute exacerbations of hepatitis B ... may likewise occur with discontinuation of BIKTARVY.
FDA label (17): counseling text repeating that discontinuation may cause severe acute exacerbations.
Unsupported Statements
Contradictions
Important Omissions
Any explicit patient counseling element (e.g., advising patients to not discontinue BIKTARVY without first informing their healthcare provider).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim and supporting statements align with the label warning and associated monitoring guidance for discontinuation-related hepatitis B exacerbations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One label counseling detail about not discontinuing without informing a healthcare provider is not explicitly included in the provided evaluation statements.
Suggested Improvement
If describing patient-facing discontinuation guidance, add the counseling instruction from section 17: advise the patient to not discontinue BIKTARVY without first informing their healthcare provider.